RBC Capital sets a new price target for Johnson & Johnson (NYSE:JNJ) at $209, indicating a potential increase of approximately 9.26%.The potential acquisition of Protagonist Therapeutics could significantly expand JNJ's pharmaceutical portfolio.FDA approval of Simponi for children with ulcerative colitis underscores JNJ's commitment to addressing unmet medical needs.Johnson & Johnson (NYSE: JNJ) is a well-established company known for its diverse range of products in the healthcare sector, including pharmac ...

Earnings Report - Johnson & Johnson is set to release its third-quarter earnings results on October 14, with expected earnings of $2.76 per share, an increase from $2.42 per share in the same period last year [1] - The company projects quarterly revenue of $23.76 billion, compared to $22.47 billion a year earlier [1] FDA Approval - The U.S. FDA has approved Johnson & Johnson's Simponi (golimumab) for children with moderately to severely active ulcerative colitis who weigh at least 15 kg [2] - Following the FDA approval, shares of Johnson & Johnson rose by 0.7% to close at $191.08 [2] Analyst Ratings and Price Targets - Goldman Sachs analyst Asad Haider maintained a Buy rating and raised the price target from $186 to $212 [5] - Citigroup analyst Joanne Wuensch also maintained a Buy rating, increasing the price target from $200 to $213 [5] - B of A Securities analyst Tim Anderson maintained a Neutral rating and raised the price target from $175 to $198 [5] - Guggenheim analyst Vamil Divan upgraded the stock from Neutral to Buy, raising the price target from $167 to $206 [5] - JP Morgan analyst Michael Weinstein maintained a Neutral rating and increased the price target from $185 to $200 [5]

Johnson & Johnson (NYSE:JNJ) will release earnings results for the third quarter, before the opening bell on Tuesday, Oct. 14.Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.76 per share, up from $2.42 per share in the year-ago period. Johnson & Johnson projects quarterly revenue of $23.76 billion, compared to $22.47 billion a year earlier, according to data from Benzinga Pro.On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's S ...